



## ARTICLE

# The Renaissance of Healthcare Logistics Part 3: Investment Opportunities and Implications

## Attractive investment opportunities in healthcare logistics

Healthcare logistics presents a compelling investment profile defined by high barriers to entry, recurring contract revenue, attractive margins, resilient growth and clear paths to scale.

- **High barriers to entry:** Healthcare logistics requires specialized knowledge (which is highly concentrated and rare), strict regulatory compliance (e.g., good manufacturing practice, or GMP; good distribution practice (GDP); chain-of-custody standards), validated processes and expensive temperature-controlled infrastructure. These barriers limit new entrants and protect incumbents.
- **Fragmented market structure:** Many brokers, cold-chain providers, couriers and niche 3PLs remain small and regionally focused. This fragmentation creates clear opportunities for consolidation, roll-ups and capability integration.
- **Recurring revenue and contractual stability:** Long-term contracts with pharmaceutical companies, medtechs, contract research organizations, labs and hospitals provide predictable, recurring revenue streams with strong customer retention.
- **Attractive margin profiles:** Margins are supported by specialized expertise, regulatory credibility and the urgent, mission-critical nature of shipments. Time sensitivity and compliance risk allow providers to command premium pricing.
- **Growth and structural resilience:** Demand is fueled by biologics, clinical trials, diagnostics, personalized medicine, aging populations and chronic disease prevalence. End markets are significantly less cyclical than in traditional freight.

- **Scalability and platform creation:** Operators can integrate multiple regional players into national or global platforms, expanding service breadth and geographic coverage while capturing operational synergies.
- **Global expansion opportunities:** Cross-border pharmaceutical flows, clinical trial activity and international biologics distribution create opportunities for network expansion and freight forwarding capabilities.
- **Strategic assets:** Operators have the option to underpin their competitive position with ownership of specialized and differentiation assets such as GDP-certified cold storage and cross-docking facilities or hard-to-replicate fleet networks for compliant cold-chain last-mile services.
- **Diverse strategic exit pathways:** Scaled, specialized platforms represent attractive acquisition targets for global integrators, healthcare-focused 3PLs and pharma services providers seeking capability enhancement.
- **Opportunities for AI disruptive growth:** Significant potential exists for value creation and disruptive growth in a data-rich environment with AI multiple expansion tailwinds.

There is a wide range of potential areas for investment. A selection of high-value healthcare logistics segments includes:

- **Preclinical and R&D:** R&D samples, bulk drugs and application programming interfaces
- **Clinical trials:** Vaccines and investigational medicinal products
- **Biological samples:** Reagents, patient samples and collection kits
- **Cell and gene therapy:** Autologous and allogeneic therapies requiring ultracontrolled handling
- **Blood and reproductive materials:** Bone marrow, cord blood, eggs, sperm and embryos
- **Organ and tissue transport:** Organs, grafts, heart valves and other life-critical materials
- **Direct-to-patient/direct-to-provider:** Clinical drug therapies and medical devices
- **Specialized medical and lab equipment:** High-value, sensitive instruments
- **Durable medical equipment:** Long-term patient devices such as mobility aids and respiratory equipment

These segments share common characteristics: regulatory scrutiny, time sensitivity, temperature control and high consequence of failure. Investment interest is additionally strong in operators offering the following services:

- **Cold storage and temperature-controlled warehousing:** Continuous monitoring of temperature and humidity with GMP/GDP compliance
- **Courier and final-mile delivery:** Secure, chain-of-custody transport to hospitals, clinics, pharmacies or patients

- **Time-critical and expedited transportation:** Guaranteed delivery windows for organs, biologics and clinical trial materials
- **Freight forwarding and customs brokerage:** Cross-border expertise for pharmaceuticals and medical equipment
- **Clinical trial supply chain management:** End-to-end storage, labeling, distribution and tracking services
- **Medical device and equipment logistics:** White-glove handling, installation and technical services
- **Reverse logistics:** Recalls, reprocessing and compliant disposal of regulated materials
- **AI-enabled orchestration and visibility platforms:** Predictive routing, temperature analytics, risk scoring and exception management

Increasingly, value creation is driven not only by physical infrastructure, but also by data integration, automation and AI-enabled decision support layered across these services.

### Implications for strategics, investors and founders

The current environment is creating a distinct sense of urgency for both financial and strategic buyers to secure high-quality assets before competitive intensity further increases.

#### Strategics: A narrowing window

In the period immediately following the last freight cycle, private equity participation was comparatively muted, providing corporates with a unique opportunity to acquire niche healthcare operators. That window is closing rapidly as financial sponsors reenter resilient verticals with conviction.

Strategic buyers now face several pressures:

- The need to acquire or partner with AI-enabled, niche operators to defend and expand market share
- Growing competitive threat from technology-native entrants without legacy infrastructure
- Increasing customer expectations for integrated, end-to-end, data-driven solutions

Corporations that delay risk are encountering heightened competition, higher valuation multiples and reduced availability of scaled, high-quality targets.

#### Private equity: Capability-driven platform strategies

For private equity, healthcare logistics remains one of the most attractive areas within the broader transportation and supply chain sector.

Key themes include:

- Continued opportunity to consolidate fragmented parts of the ecosystem (e.g., brokers, cold-chain operators and last-mile providers), roll-up strategies that are increasingly capability-driven, combining cold chain, final mile, clinical trial management, customs expertise and data visibility into integrated offerings
- Focus on solution control rather than network density alone, using tech-enabled capabilities to deliver differentiated value that supports premium pricing and longer customer contracts

Importantly, many sponsors are underwriting exits to strategic buyers rather than other financial sponsors. As a result, platforms are being designed from inception to fill clear capability gaps for global integrators and healthcare-focused 3PLs, with early investment in governance, reporting infrastructure and integration readiness.

### **Family- and founder-owned operators: A generational opportunity**

Historically run for steady cash flow and long-standing customer relationships, many family- and founder-owned healthcare logistics businesses are being re-rated as institutional-quality assets. Their domain expertise, regulatory credibility and embedded customer trust represent significant strategic value.

Many owners underestimate how attractive their businesses are to both strategic and financial buyers. With strong demand across the buyer universe, founders have a unique opportunity to unlock growth capital, accelerate technology and AI enablement, expand geographically, broaden service offerings, and professionalize systems and management infrastructure.

A wide range of transaction structures — including minority investments, structured partnerships and majority sales with meaningful equity rollover — allow founders to retain leadership and participate in a second, often larger value-creation event.

For more information, please [contact us](#).

## About the Authors

### L.E.K. Consulting



#### **Ilya Trakhtenberg**

Ilya Trakhtenberg is a Managing Director in L.E.K. Consulting's Chicago office and leader of the firm's Healthcare Supply Chain practice. Ilya is a senior member of the MedTech practice and founded L.E.K.'s MedTech Launch Center of Excellence. He serves as a pragmatic, strategic adviser to corporate and private equity clients on accelerating business growth, developing and launching new products, and enabling growth execution (e.g., commercial excellence, supply chain optimization).



#### **Jock Fullmer**

Jock Fullmer is an Engagement Manager in L.E.K. Consulting's Chicago office and is aligned with the firm's MedTech & Healthcare Supply Chain practice. Jock's experience covers a range of mission-critical topics for players in the healthcare ecosystem including commercial/GTM strategy, growth strategy and M&A.

## About the Authors

### Lincoln International



#### **Ryan McDermott**

Ryan McDermott is a senior officer in Lincoln International's Transportation & Logistics Group. He has extensive experience advising private equity firms, as well as public and privately held companies, on mergers and acquisitions. He specializes in healthcare and pharmaceutical logistics, specialty transportation, white-glove logistics, specialized freight forwarding & brokerage, and transportation and logistics infrastructure. He brings deep sector insight and transaction expertise to sharpen strategic positioning, clearly articulate differentiated value, and proactively address key diligence considerations to deliver strong outcomes for clients.



#### **Dirk Engelmann**

Dirk Engelmann is a Managing Director in Lincoln International's Frankfurt office and serves as Europe and ROW Head of the firm's Transportation & Logistics sector. He advises corporate clients and private equity investors on domestic and cross-border mergers and acquisitions. He specializes in transportation and logistics transactions, with additional experience across the healthcare, engineering, consumer goods, and aviation sectors, much of which has been gained through executing complex international deals. Dirk oversees the full transaction lifecycle, from origination through execution, leveraging best practices and current market insights across valuation, due diligence, and process management.



#### **Gaurang Shastri**

Gaurang Shastri is a Managing Director in Lincoln International's Chicago office and serves as Head of North America for the firm's Transportation & Logistics sector. He brings over 20 years of experience advising leading private equity firms, Fortune 500 companies, entrepreneurs, and private business owners on mergers and acquisitions. His experience spans a broad range of sub-sectors, including 3PL and 4PL services, aftermarket services, aviation services, e-commerce fulfillment, freight forwarding, intermodal and drayage, last mile logistics, marine services, pallet management, rail services, reverse logistics, and warehousing and distribution. Gaurang is also a frequent contributor to leading media outlets, including Bloomberg Radio, Inbound Logistics, and Transport Topics.



#### **Justin Berkson**

Justin Berkson is an Associate in Lincoln International's Transportation & Logistics Group. He focuses on advising private equity firms, as well as public and privately held companies, on mergers and acquisitions. He has experience across a range of transportation and logistics subsectors and brings strong analytical rigor, sector insight and transaction experience to support clients in evaluating strategic alternatives, positioning assets effectively and navigating complex processes.

**About Lincoln International**

We are trusted investment banking advisors to business owners and senior executives of leading private equity firms and their portfolio companies and to public and privately held companies around the world. Our services include mergers and acquisitions advisory, private funds and capital markets advisory, and valuations and fairness opinions. As one tightly integrated team of more than 850 professionals in more than 20 offices in 15 countries, we offer an unobstructed perspective on the global private capital markets, backed by superb execution and a deep commitment to client success. With extensive industry knowledge and relationships, timely market intelligence and strategic insights, we forge deep, productive client relationships that endure for decades. Connect with us to learn more at [www.lincolnternational.com](http://www.lincolnternational.com).

**About L.E.K. Consulting**

We're L.E.K. Consulting, a global strategy consultancy working with business leaders to seize competitive advantage and amplify growth. Our insights are catalysts that reshape the trajectory of our clients' businesses, uncovering opportunities and empowering them to master their moments of truth. Since 1983, our worldwide practice — spanning the Americas, Asia-Pacific and Europe — has guided leaders across all industries, from global corporations to emerging entrepreneurial businesses and private equity investors. Looking for more? Visit [www.lek.com](http://www.lek.com).

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2026 L.E.K. Consulting LLC